DexCom, Inc. (DXCM) on Decifer

Decifer ranks DXCM number 139 of 269 tracked names on durable business quality.

Why it ranks here

• Sales are growing about 16% a year, faster than 60 in 100 companies we measure.
• It keeps about 23 cents of every sales dollar as cash, safer than 86 in 100 companies we measure.
• It earns about 17% a year on the money put into the business, better than 78 in 100 companies we measure.
• It costs about 32 times its yearly profit; the middle of its industry is 34. Cheaper than 60 in 100 companies we measure, against their own industries.

The current read

The evidence on DXCM lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• GLP-1 & Metabolic Disease Wave: GLP-1 receptor agonists have demonstrated large-scale efficacy in obesity and diabetes, triggering a multi-hundred-billion-dollar demand and capex surge across pharma and diabetes-device makers.

Read the full DXCM research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.